Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Assessment of myocardial viability by nuclear imaging in coronary heart disease

Prem Soman, MD, PhD, FACC, FRCP (UK)
James E Udelson, MD, FACC
Section Editor
Jeroen J Bax, MD, PhD
Deputy Editor
Brian C Downey, MD, FACC


Coronary heart disease (CHD) is the major cause of heart failure [1]. (See "Epidemiology and causes of heart failure".)

In the past, severe left ventricular (LV) dysfunction was considered an irreversible condition, as regional akinesis was thought to represent infarcted myocardial tissue. It is now understood that, among patients with ischemic cardiomyopathy, LV systolic dysfunction can result from myocardial necrosis and remodeling, myocardial hibernation, or repetitive myocardial stunning. While myocardial necrosis is irreversible, systolic dysfunction resulting from hibernation and stunning are potentially reversible states of ventricular dysfunction. (See "Pathophysiology of stunned or hibernating myocardium".)

Most patients with chronic heart failure have an admixture of all three pathophysiologic entities [2]. Clinical studies have shown that viable myocardium can be demonstrated in a substantial number of patients with CHD and LV dysfunction, even in the absence of angina [2-5]. (See "Evaluation of hibernating myocardium" and "Ischemic cardiomyopathy: Treatment and prognosis".)

In patients with significant amounts of viable myocardium, LV function may improve markedly, and even normalize, following successful revascularization (figure 1) [6-8]. An estimated 20 to 40 percent of patients with chronic ischemic LV dysfunction have the potential for significant improvement in LV function after revascularization [9]. (See "Ischemic cardiomyopathy: Treatment and prognosis".)

The outcome following revascularization is dependent not only on the presence but also the extent of viability, and a critical threshold mass of viable myocardium may be necessary for functional recovery and prognostic benefit to occur from revascularization [10-13]. Therefore, while several clinical and laboratory parameters including anginal symptoms, absence of Q waves on the electrocardiogram, and regional hypokinesis (as opposed to akinesis) on echocardiography indicate the presence of some viability, a systematic assessment of the degree and extent of viability is generally thought to be helpful for management planning and prognostication.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jan 13, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998; 97:282.
  2. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.
  3. Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003; 362:14.
  4. Schinkel AF, Bax JJ, Sozzi FB, et al. Prevalence of myocardial viability assessed by single photon emission computed tomography in patients with chronic ischaemic left ventricular dysfunction. Heart 2002; 88:125.
  5. Auerbach MA, Schöder H, Hoh C, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999; 99:2921.
  6. Rees G, Bristow JD, Kremkau EL, et al. Influence of aortocoronary bypass surgery on left ventricular performance. N Engl J Med 1971; 284:1116.
  7. Chatterjee K, Swan HJ, Parmley WW, et al. Influence of direct myocardial revascularization on left ventricular asynergy and function in patients with coronary heart disease. With and without previous myocardial infarction. Circulation 1973; 47:276.
  8. Brundage BH, Massie BM, Botvinick EH. Improved regional ventricular function after successful surgical revascularization. J Am Coll Cardiol 1984; 3:902.
  9. Bonow RO. Identification of viable myocardium. Circulation 1996; 94:2674.
  10. Ragosta M, Beller GA, Watson DD, et al. Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87:1630.
  11. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884.
  12. Senior R, Kaul S, Raval U, Lahiri A. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 2002; 9:454.
  13. Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996; 28:558.
  14. Weich HF, Strauss HW, Pitt B. The extraction of thallium-201 by the myocardium. Circulation 1977; 56:188.
  15. Pohost GM, Zir LM, Moore RH, et al. Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201. Circulation 1977; 55:294.
  16. Liu P, Kiess MC, Okada RD, et al. The persistent defect on exercise thallium imaging and its fate after myocardial revascularization: does it represent scar or ischemia? Am Heart J 1985; 110:996.
  17. Rozanski A, Berman DS, Gray R, et al. Use of thallium-201 redistribution scintigraphy in the preoperative differentiation of reversible and nonreversible myocardial asynergy. Circulation 1981; 64:936.
  18. Gibson RS, Watson DD, Taylor GJ, et al. Prospective assessment of regional myocardial perfusion before and after coronary revascularization surgery by quantitative thallium-201 scintigraphy. J Am Coll Cardiol 1983; 1:804.
  19. Nelson CW, Wilson RA, Angello DA, Palac RT. Effect of thallium-201 blood levels on reversible myocardial defects. J Nucl Med 1989; 30:1172.
  20. Cloninger KG, DePuey EG, Garcia EV, et al. Incomplete redistribution in delayed thallium-201 single photon emission computed tomographic (SPECT) images: an overestimation of myocardial scarring. J Am Coll Cardiol 1988; 12:955.
  21. Gutman J, Berman DS, Freeman M, et al. Time to completed redistribution of thallium-201 in exercise myocardial scintigraphy: relationship to the degree of coronary artery stenosis. Am Heart J 1983; 106:989.
  22. Yang LD, Berman DS, Kiat H, et al. The frequency of late reversibility in SPECT thallium-201 stress-redistribution studies. J Am Coll Cardiol 1990; 15:334.
  23. Kiat H, Berman DS, Maddahi J, et al. Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 1988; 12:1456.
  24. Perrone-Filardi P, Pace L, Prastaro M, et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. Circulation 1996; 94:2712.
  25. Dilsizian V, Rocco TP, Freedman NM, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990; 323:141.
  26. Ohtani H, Tamaki N, Yonekura Y, et al. Value of thallium-201 reinjection after delayed SPECT imaging for predicting reversible ischemia after coronary artery bypass grafting. Am J Cardiol 1990; 66:394.
  27. Rocco TP, Dilsizian V, McKusick KA, et al. Comparison of thallium redistribution with rest "reinjection" imaging for the detection of viable myocardium. Am J Cardiol 1990; 66:158.
  28. Inglese E, Brambilla M, Dondi M, et al. Assessment of myocardial viability after thallium-201 reinjection or rest-redistribution imaging: a multicenter study. The Italian Group of Nuclear Cardiology. J Nucl Med 1995; 36:555.
  29. Tamaki N, Ohtani H, Yamashita K, et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991; 32:673.
  30. Dilsizian V, Bonow RO. Differential uptake and apparent 201Tl washout after thallium reinjection. Options regarding early redistribution imaging before reinjection or late redistribution imaging after reinjection. Circulation 1992; 85:1032.
  31. Gewirtz H, Beller GA, Strauss HW, et al. Transient defects of resting thallium scans in patients with coronary artery disease. Circulation 1979; 59:707.
  32. Berger BC, Watson DD, Burwell LR, et al. Redistribution of thallium at rest in patients with stable and unstable angina and the effect of coronary artery bypass surgery. Circulation 1979; 60:1114.
  33. Dilsizian V, Perrone-Filardi P, Arrighi JA, et al. Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium. Comparison with metabolic activity by positron emission tomography. Circulation 1993; 88:941.
  34. Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation 1991; 83:26.
  35. Udelson JE, Coleman PS, Metherall J, et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation 1994; 89:2552.
  36. Basu S, Senior R, Raval U, Lahiri A. Superiority of nitrate-enhanced 201Tl over conventional redistribution 201Tl imaging for prognostic evaluation after myocardial infarction and thrombolysis. Circulation 1997; 96:2932.
  37. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82:1826.
  38. Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation 1988; 77:491.
  39. Li QS, Solot G, Frank TL, et al. Myocardial redistribution of technetium-99m-methoxyisobutyl isonitrile (SESTAMIBI). J Nucl Med 1990; 31:1069.
  40. Taillefer R, Primeau M, Costi P, et al. Technetium-99m-sestamibi myocardial perfusion imaging in detection of coronary artery disease: comparison between initial (1-hour) and delayed (3-hour) postexercise images. J Nucl Med 1991; 32:1961.
  41. Sinusas AJ, Bergin JD, Edwards NC, et al. Redistribution of 99mTc-sestamibi and 201Tl in the presence of a severe coronary artery stenosis. Circulation 1994; 89:2332.
  42. Marzullo P, Parodi O, Reisenhofer B, et al. Value of rest thallium-201/technetium-99m sestamibi scans and dobutamine echocardiography for detecting myocardial viability. Am J Cardiol 1993; 71:166.
  43. Altehoefer C, vom Dahl J, Biedermann M, et al. Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: comparison with fluorine-18-FDG PET. J Nucl Med 1994; 35:569.
  44. Bisi G, Sciagrà R, Santoro GM, Fazzini PF. Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J Am Coll Cardiol 1994; 24:1282.
  45. Galli M, Marcassa C, Imparato A, et al. Effects of nitroglycerin by technetium-99m sestamibi tomoscintigraphy on resting regional myocardial hypoperfusion in stable patients with healed myocardial infarction. Am J Cardiol 1994; 74:843.
  46. Sciagrà R, Pellegri M, Pupi A, et al. Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2000; 36:739.
  47. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003; 108:1404.
  48. Flotats A, Carrió I, Estorch M, et al. Nitrate administration to enhance the detection of myocardial viability by technetium-99m tetrofosmin single-photon emission tomography. Eur J Nucl Med 1997; 24:767.
  49. Giorgetti A, Marzullo P, Sambuceti G, et al. Baseline/post-nitrate Tc-99m tetrofosmin mismatch for the assessment of myocardial viability in patients with severe left ventricular dysfunction: comparison with baseline Tc-99m tetrofosmin scintigraphy/FDG PET imaging. J Nucl Cardiol 2004; 11:142.
  50. Levine MG, McGill CC, Ahlberg AW, et al. Functional assessment with electrocardiographic gated single-photon emission computed tomography improves the ability of technetium-99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization. Am J Cardiol 1999; 83:1.
  51. Kitsiou AN, Srinivasan G, Quyyumi AA, et al. Stress-induced reversible and mild-to-moderate irreversible thallium defects: are they equally accurate for predicting recovery of regional left ventricular function after revascularization? Circulation 1998; 98:501.
  52. Schelbert HR. Metabolic imaging to assess myocardial viability. J Nucl Med 1994; 35:8S.
  53. Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992; 19:874.
  54. Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989; 64:860.
  55. Marwick TH, MacIntyre WJ, Lafont A, et al. Metabolic responses of hibernating and infarcted myocardium to revascularization. A follow-up study of regional perfusion, function, and metabolism. Circulation 1992; 85:1347.
  56. Carrel T, Jenni R, Haubold-Reuter S, et al. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992; 6:479.
  57. Gropler RJ, Geltman EM, Sampathkumaran K, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 1992; 20:569.
  58. Tamaki N, Kawamoto M, Tadamura E, et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation 1995; 91:1697.
  59. Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92:3436.
  60. Gerber BL, Ordoubadi FF, Wijns W, et al. Positron emission tomography using(18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Positron Emission Tomography for the Detection of Myocardial Viability. Eur Heart J 2001; 22:1691.
  61. Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002; 40:1735.
  62. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30:1693.
  63. Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994; 90:2687.
  64. Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 2001; 37:81.
  65. Marin-Neto JA, Dilsizian V, Arrighi JA, et al. Thallium scintigraphy compared with 18F-fluorodeoxyglucose positron emission tomography for assessing myocardial viability in patients with moderate versus severe left ventricular dysfunction. Am J Cardiol 1998; 82:1001.
  66. Rohatgi R, Epstein S, Henriquez J, et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol 2001; 87:1096.
  67. Kerrou K, Toussaint JF, Froissart M, Talbot JN. Myocardial viability assessment with FDG imaging: comparison of PET, SPECT, and gamma-camera coincidence detection. J Nucl Med 2000; 41:2099.
  68. Mabuchi M, Kubo N, Morita K, et al. Value and limitation of myocardial fluorodeoxyglucose single photon emission computed tomography using ultra-high energy collimators for assessing myocardial viability. Nucl Med Commun 2002; 23:879.
  69. Fitzgerald J, Parker JA, Danias PG. F-18 fluoro deoxyglucose SPECT for assessment of myocardial viability. J Nucl Cardiol 2000; 7:382.
  70. Bax JJ, Cornel JH, Visser FC, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol 1997; 30:377.
  71. Sato H, Iwasaki T, Toyama T, et al. Prediction of functional recovery after revascularization in coronary artery disease using (18)F-FDG and (123)I-BMIPP SPECT. Chest 2000; 117:65.
  72. Srinivasan G, Kitsiou AN, Bacharach SL, et al. [18F]fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation 1998; 97:843.
  73. De Boer J, Slart RH, Blanksma PK, et al. Comparison of 99mTc-sestamibi-18F-fluorodeoxyglucose dual isotope simultaneous acquisition and rest-stress 99mTc-sestamibi single photon emission computed tomography for the assessment of myocardial viability. Nucl Med Commun 2003; 24:251.
  74. Fukuchi K, Katafuchi T, Fukushima K, et al. Estimation of myocardial perfusion and viability using simultaneous 99mTc-tetrofosmin--FDG collimated SPECT. J Nucl Med 2000; 41:1318.
  75. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 1972; 15:289.
  76. Goldstein RA, Klein MS, Welch MJ, Sobel BE. External assessment of myocardial metabolism with C-11 palmitate in vivo. J Nucl Med 1980; 21:342.
  77. Schön HR, Schelbert HR, Robinson G, et al. C- 11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. I. Kinetics of C- 11 palmitic acid in normal myocardium. Am Heart J 1982; 103:532.
  78. Reske SN, Biersack HJ, Lackner K, et al. Assessment of regional myocardial uptake and metabolism of omega-(p-123I-phenyl) pentadecanoic acid with serial single-photon emission tomography. Nuklearmedizin 1982; 21:249.
  79. Yang JY, Ruiz M, Calnon DA, et al. Assessment of myocardial viability using 123I-labeled iodophenylpentadecanoic acid at sustained low flow or after acute infarction and reperfusion. J Nucl Med 1999; 40:821.
  80. Caldwell JH, Martin GV, Link JM, et al. Iodophenylpentadecanoic acid-myocardial blood flow relationship during maximal exercise with coronary occlusion. J Nucl Med 1990; 31:99.
  81. Murray G, Schad N, Ladd W, et al. Metabolic cardiac imaging in severe coronary disease: assessment of viability with iodine-123-iodophenylpentadecanoic acid and multicrystal gamma camera, and correlation with biopsy. J Nucl Med 1992; 33:1269.
  82. Hansen CL, Heo J, Oliner C, et al. Prediction of improvement in left ventricular function with iodine-123-IPPA after coronary revascularization. J Nucl Med 1995; 36:1987.
  83. Iskandrian AS, Powers J, Cave V, et al. Assessment of myocardial viability by dynamic tomographic iodine 123 iodophenylpentadecanoic acid imaging: comparison with rest-redistribution thallium 201 imaging. J Nucl Cardiol 1995; 2:101.
  84. Verani MS, Taillefer R, Iskandrian AE, et al. 123I-IPPA SPECT for the prediction of enhanced left ventricular function after coronary bypass graft surgery. Multicenter IPPA Viability Trial Investigators. 123I-iodophenylpentadecanoic acid. J Nucl Med 2000; 41:1299.
  85. Tamaki N, Tadamura E, Kawamoto M, et al. Decreased uptake of iodinated branched fatty acid analog indicates metabolic alterations in ischemic myocardium. J Nucl Med 1995; 36:1974.
  86. Knapp FF Jr, Goodman MM, Callahan AP, Kirsch G. Radioiodinated 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid: a useful new agent to evaluate myocardial fatty acid uptake. J Nucl Med 1986; 27:521.
  87. Tamaki N, Kawamoto M, Yonekura Y, et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992; 33:659.
  88. Hambÿe AS, Vaerenberg MM, Dobbeleir AA, et al. Abnormal BMIPP uptake in chronically dysfunctional myocardial segments: correlation with contractile response to low-dose dobutamine. J Nucl Med 1998; 39:1845.
  89. Kudoh T, Tadamura E, Tamaki N, et al. Iodinated free fatty acid and 201T1 uptake in chronically hypoperfused myocardium: histologic correlation study. J Nucl Med 2000; 41:293.
  90. Franken PR, Dendale P, De Geeter F, et al. Prediction of functional outcome after myocardial infarction using BMIPP and sestamibi scintigraphy. J Nucl Med 1996; 37:718.
  91. Ito T, Tanouchi J, Kato J, et al. Recovery of impaired left ventricular function in patients with acute myocardial infarction is predicted by the discordance in defect size on 123I-BMIPP and 201Tl SPET images. Eur J Nucl Med 1996; 23:917.
  92. Hashimoto A, Nakata T, Tsuchihashi K, et al. Postischemic functional recovery and BMIPP uptake after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction. Am J Cardiol 1996; 77:25.
  93. Naruse H, Arii T, Kondo T, et al. Clinical usefulness of iodine 123-labeled fatty acid imaging in patients with acute myocardial infarction. J Nucl Cardiol 1998; 5:275.
  94. Bax JJ, Poldermans D, Elhendy A, et al. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001; 26:147.
  95. Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004; 25:815.
  96. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445.
  97. Tarakji KG, Brunken R, McCarthy PM, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006; 113:230.
  98. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011; 364:1617.
  99. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007; 50:2002.